2002
DOI: 10.1007/bf02287829
|View full text |Cite
|
Sign up to set email alerts
|

Access to new medications to treat schizophrenia

Abstract: Between 1989 and 1997, the Food and Drug Administration approved four new-generation antipsychotic medications for use in the treatment of schizophrenia. This article examines factors associated with the use of new antipsychotic medications as compared with traditional antipsychotic medications from patient interviews, medical records, and a physician survey administered at schizophrenia treatment sites around the country as part of the Schizophrenia Care and Assessment Program. The following variables were si… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
55
0

Year Published

2003
2003
2016
2016

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 33 publications
(56 citation statements)
references
References 36 publications
1
55
0
Order By: Relevance
“…Despite this progress, a significant proportion of seriously mentally ill patients continue to receive sub-optimal pharmacological treatment and under-utilize appropriate treatments (Lehman et al, 1998;Young, Sullivan, Burnam, & Brook, 1998). Previous studies have found less adequate care for African American patients than whites in their lower use of newer types of psychotropic medications, fewer outpatient visits and more emergency room/crisis contacts (Covell, Jackson, Evans, & Essock, 2002;Daumit et al, 2003;Hu, Snowden, & Jerrell 1992;Kuno & Rothbard, 2002;Mark, Dirani, Slade, & Russo, 2002;Rothbard, Kuno, & Foley, 2003;Snowden & Holschuh, 1992;Snowden & Thomas, 2000;Wang, West, Tanielian, & Pincus, 2000).…”
Section: Introductionmentioning
confidence: 95%
“…Despite this progress, a significant proportion of seriously mentally ill patients continue to receive sub-optimal pharmacological treatment and under-utilize appropriate treatments (Lehman et al, 1998;Young, Sullivan, Burnam, & Brook, 1998). Previous studies have found less adequate care for African American patients than whites in their lower use of newer types of psychotropic medications, fewer outpatient visits and more emergency room/crisis contacts (Covell, Jackson, Evans, & Essock, 2002;Daumit et al, 2003;Hu, Snowden, & Jerrell 1992;Kuno & Rothbard, 2002;Mark, Dirani, Slade, & Russo, 2002;Rothbard, Kuno, & Foley, 2003;Snowden & Holschuh, 1992;Snowden & Thomas, 2000;Wang, West, Tanielian, & Pincus, 2000).…”
Section: Introductionmentioning
confidence: 95%
“…These discrepancies involve lower use of newer psychotropic medications, fewer outpatient visits and more emergency room/crisis contacts in African American patients compared to Caucasians (Covell et al 2002;Daumit et al 2003;Hu et al 1992;Kuno and Rothbard 2002;Mark et al 2002;Rothbard et al 2003;Snowden and Holschuh 1992;Snowden and Thomas 2000;Wang et al 2000). Furthermore, a study by investigators found variation in treatment patterns based on the geographic location of service providers within the same public mental health system.…”
Section: Introductionmentioning
confidence: 90%
“…Data were obtained from interviews, clinical assessments, and medical records reviews. Recent studies providing additional information on the SCAP are Mark et al (2002), Slade and Salkever (2001), and Swanson et al (In press). …”
Section: Study Settingmentioning
confidence: 96%